Navigating Cohort Management in Early Phase Oncology Trials
Navigating Cohort Management in Early Phase Oncology Trials Read More »
Expansion Brings New Principal Investigators, Expanded Site Resources, and Accelerated Trial Initiation to Support Breakthrough Blood Cancer Therapies 10 December 2024 The START Center for Cancer Research (“START”), the world’s largest community-based early phase cancer trial site network, has announced the expansion of its capabilities to support early phase hematological cancer trials globally. This expansion
The integration of wearable technology into early-phase cancer trials represents a pivotal moment in oncology research, offering the ability to transform how we assess and predict clinical outcomes for patients. Traditional methods such as the Karnofsky Performance Status (developed in 1948) and ECOG Performance Status (introduced in 1982) have been the gold standard for decades.
28 October 2024 The START Center for Cancer Research (“START”), a global leader in early-phase cancer clinical trials, today announced a new strategic partnership with the Fundación Rioja Salud, a foundation dedicated to (i) the promotion and protection of health, (ii) the training, teaching, research, development and innovation of Health Sciences and biotechnology, what includes
START Dublin will offer patients with advanced cancer the opportunity to participate in cutting edge research and enhance the availability of new cancer drugs 14 October 2024 The Minister for Public Expenditure, NDP Delivery and Reform, Paschal Donohoe TD has today (Monday) officially opened START Dublin, the Republic of Ireland’s first dedicated Phase I Clinical
San Antonio, TX – October 8, 2024. The START Center for Cancer Research (“START”) proudly announces that Amita Patnaik, MD, FRCPC, has been named to the prestigious PharmaVoice 100 list as a “Cancer Care Visionary.” This annual award celebrates inspiring individuals in life sciences who are making a profound impact on the field and driving
Dr. Takimoto to propel scientific and medical strategies and advance START’s leadership in global early-phase cancer research San Antonio, TX – October 2, 2024. The START Center for Cancer Research (“START”) proudly announces the appointment of Chris H. Takimoto, MD, PhD, FACP, as its new Chief Medical Officer. Dr. Takimoto, a renowned physician-scientist, oncology drug